News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
334,037 Results
Type
Article (19086)
Company Profile (93)
Press Release (314858)
Section
Business (89192)
Career Advice (1324)
Deals (17496)
Drug Delivery (62)
Drug Development (61233)
Employer Resources (61)
FDA (9093)
Job Trends (7499)
News (174302)
Policy (15224)
Tag
2024 BioForest Digital (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (13)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (6)
2024 Genetown Standard (7)
2024 Pharm Country Standard (3)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (2)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Genetown Elite (1)
Academia (1214)
Academic (1)
Accelerated approval (2)
Adcomms (14)
Allergies (60)
Alliances (17768)
ALS (59)
Alzheimer's disease (914)
Antibody-drug conjugate (ADC) (81)
Approvals (9124)
Artificial intelligence (121)
Autoimmune disease (10)
Automation (5)
Bankruptcy (139)
Best Places to Work (6369)
BIOSECURE Act (7)
Biosimilars (62)
Biotechnology (62)
Bladder cancer (52)
Brain cancer (21)
Breast cancer (235)
Cancer (1588)
Cardiovascular disease (125)
Career advice (1042)
Career pathing (15)
CAR-T (89)
Cell therapy (249)
Cervical cancer (16)
Clinical research (51241)
Collaboration (416)
Compensation (180)
Complete response letters (9)
COVID-19 (2203)
CRISPR (17)
C-suite (74)
Cystic fibrosis (62)
Data (1684)
Denatured (1)
Depression (25)
Diabetes (220)
Diagnostics (3370)
Digital health (5)
Diversity (1)
Diversity, equity & inclusion (8)
Drug discovery (67)
Drug pricing (50)
Drug shortages (22)
Duchenne muscular dystrophy (59)
Earnings (53058)
Editorial (19)
Employer branding (11)
Employer resources (52)
Events (53218)
Executive appointments (219)
FDA (9901)
Featured Employer (44)
Friedreich's ataxia (1)
Frontotemporal dementia (2)
Funding (415)
Gene editing (51)
Generative AI (9)
Gene therapy (175)
GLP-1 (637)
Government (2385)
Grass and pollen (3)
Guidances (38)
Healthcare (9660)
Huntington's disease (13)
IgA nephropathy (19)
Immunology and inflammation (81)
Indications (21)
Infectious disease (2277)
Inflammatory bowel disease (90)
Inflation Reduction Act (5)
Influenza (34)
Intellectual property (59)
Interviews (243)
IPO (10158)
IRA (17)
Job creations (1451)
Job search strategy (908)
Kidney cancer (10)
Labor market (23)
Layoffs (228)
Leadership (10)
Legal (2471)
Liver cancer (49)
Lung cancer (242)
Lymphoma (108)
Management (17)
Manufacturing (135)
MASH (54)
Medical device (6342)
Medtech (6342)
Mergers & acquisitions (7649)
Metabolic disorders (561)
Multiple sclerosis (61)
NASH (17)
Neurodegenerative disease (62)
Neuropsychiatric disorders (17)
Neuroscience (1267)
NextGen: Class of 2025 (2659)
Non-profit (1846)
Northern California (1569)
Now hiring (7)
Obesity (317)
Opinion (100)
Ovarian cancer (54)
Pain (56)
Pancreatic cancer (55)
Parkinson's disease (108)
Partnered (11)
Patents (100)
Patient recruitment (71)
Peanut (35)
People (15485)
Pharmaceutical (27)
Pharmacy benefit managers (3)
Phase I (14521)
Phase II (25281)
Phase III (16496)
Pipeline (925)
Podcasts (22)
Policy (48)
Postmarket research (1587)
Preclinical (4824)
Press Release (30)
Prostate cancer (73)
Psychedelics (23)
Radiopharmaceuticals (149)
Rare diseases (237)
Real estate (1738)
Recruiting (29)
Regulatory (11723)
Reports (31)
Research institute (1160)
Resumes & cover letters (257)
Rett syndrome (4)
RNA editing (2)
RSV (24)
Schizophrenia (51)
Series A (64)
Series B (44)
Service/supplier (6)
Sickle cell disease (40)
Southern California (1393)
Special edition (13)
Spinal muscular atrophy (133)
Sponsored (19)
Startups (1339)
State (2)
Stomach cancer (13)
Supply chain (32)
Tariffs (6)
The Weekly (21)
United States (12833)
Vaccines (474)
Venture capitalists (15)
Webinars (4)
Weight loss (214)
Women's health (17)
Worklife (10)
Date
Today (55)
Last 7 days (462)
Last 30 days (1839)
Last 365 days (21480)
2025 (5431)
2024 (22022)
2023 (24445)
2022 (29984)
2021 (32062)
2020 (30534)
2019 (22702)
2018 (17293)
2017 (17516)
2016 (15308)
2015 (18682)
2014 (13373)
2013 (9816)
2012 (10616)
2011 (11095)
2010 (9732)
Location
Africa (408)
Alabama (29)
Alaska (1)
Arizona (65)
Arkansas (4)
Asia (21679)
Australia (3901)
California (3508)
Canada (1176)
China (352)
Colorado (139)
Connecticut (167)
Delaware (92)
Europe (48182)
Florida (460)
Georgia (133)
Idaho (25)
Illinois (224)
India (13)
Indiana (180)
Iowa (4)
Japan (113)
Kansas (45)
Kentucky (19)
Louisiana (5)
Maine (36)
Maryland (477)
Massachusetts (2594)
Michigan (95)
Minnesota (179)
Mississippi (2)
Missouri (42)
Montana (14)
Nebraska (7)
Nevada (32)
New Hampshire (37)
New Jersey (1073)
New Mexico (4)
New York (1068)
North Carolina (462)
North Dakota (2)
Northern California (1569)
Ohio (93)
Oregon (16)
Pennsylvania (749)
Puerto Rico (8)
Rhode Island (10)
South America (568)
South Carolina (5)
Southern California (1393)
Tennessee (35)
Texas (518)
Utah (95)
Virginia (62)
Washington D.C. (28)
Washington State (314)
Wisconsin (24)
334,037 Results for "2".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement
Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.
March 11, 2025
·
3 min read
·
Tristan Manalac
Press Releases
ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy
April 4, 2025
·
15 min read
Press Releases
Colorado’s Life Sciences Ecosystem Raised $2.15 Billion in 2024
Fundraising Exceeds $2B for the Second Time in Four-Year Period
December 19, 2024
·
1 min read
Press Releases
Nexus Pharmaceuticals Launches Fluorescein 2 mL
April 1, 2025
·
1 min read
Press Releases
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
March 5, 2025
·
7 min read
Obesity
Obesity Late-Comer AbbVie Inks up to $2.2B Amylin Deal With Gubra
AbbVie is joining the amylin arena, though the pharma is still far behind leaders Novo Nordisk and Eli Lilly.
March 3, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting
March 25, 2025
·
2 min read
Press Releases
Samsung Invests in C2N Diagnostics
March 13, 2025
·
4 min read
Alzheimer’s disease
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
January 23, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Hudson Therapeutics, the U.S. Subsidiary of Shaperon, Announces Initiation of Phase 2b Part 2 Clinical Trial for NuGel
March 10, 2025
·
3 min read
1 of 33,404
Next
